Ovarian cancer represents the fifth leading cause of death in women, with 5-year survival around 10%. This unfavourable prognosis figures are closely related to intrinsic or acquired resistance to conventional chemotherapy, making the active search of novel agents with relevant molecular targets crucial in the fight against this disease. In The Lancet Oncology, Jung-Min Lee and colleagues¹ report the results of a phase 2 study investigating the clinical activity of prexasertib, a cell cycle checkpoint kinase 1 and 2 (CHK1 and CHK2) inhibitor, in recurrent high-grade serous ovarian cancer.

中文翻译：

---

对抗卵巢癌的转折点？

卵巢癌是女性的第五大死亡原因，其5年生存率约为10％。这种不利的预后数字与常规化学疗法的内在或获得性耐药密切相关，这使得积极寻找具有相关分子靶点的新型药物在对抗这种疾病中至关重要。在The Lancet Oncology中，Jung-Min Lee及其同事¹报告了一项2期研究的结果，该研究调查了普瑞沙塞替尼（一种细胞周期检查点激酶1和2（CHK1和CHK2）抑制剂）在复发性高级别浆液性卵巢癌中的临床活性。